OTLK
Neutral signalScored 2026-09-13 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Outlook Therapeutics, Inc.
- Nom
- Outlook Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $127.2M
- Employés
- 17
- PDG
- Robert Charles Jahr
- Site web
- https://www.outlooktherapeutics.com
- Marché
- COEPCUEEQHOWLIOBTIPSC
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 347 923 titres (~349 995,93 $ US)
- Insiders
- Jahr Robert CharlesKENYON LAWRENCE ASukhtian Faisal Ghiath
- Total bought
-
$349,996
Avg buy (VWAP, 90d window) $1.09 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-14 | Jahr Robert Charles | Buy · P | 151,515 | $1.10 | $166,666 | Form 4 |
| 2026-08-14 | KENYON LAWRENCE A | Buy · P | 101,010 | $1.10 | $111,111 | Form 4 |
| 2026-07-29 | Sukhtian Faisal Ghiath | Buy · P | 95,398 | $1.05 | $99,996 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-13 Drivers: fundamentals. Moteurs : fondamentaux.
Despite a strong catalyst signal (insider cluster buying aligned with FDA approval of LYTENAVA and promising revenue projections), OTLK's severely distressed financial profile — with a current ratio of 0.38, negative…
The first sentence of the analysis written for OTLK on 2026-09-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.38 · operating margin -4744%
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 46.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -4506.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -4497.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -4744.3% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -4526.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -4416.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -4416.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -4416.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 0.380 | 0.644 | 0.663 | 1.395 | 3.185 | |
| Quick Ratio | 0.307 | 0.644 | 0.663 | 1.395 | 3.185 | |
| Solvency Ratio | -1.227 | -0.739 | -1.261 | -3.327 | -2.906 | |
| Cash Ratio | 0.176 | 0.351 | 0.501 | 0.882 | 2.144 | |
| Price To Earnings Ratio | -0.592 | -1.315 | -0.936 | -3.917 | -6.236 | |
| Price To Earnings Growth Ratio | 0.011 | 0.094 | 0.039 | 0.373 | 0.129 | |
| Forward Price To Earnings Growth Ratio | 0.011 | 0.094 | 0.039 | 0.373 | 0.129 | |
| Price To Earnings Diluted Ratio | -0.592 | -1.315 | -0.936 | -3.917 | -6.236 | |
| Price To Earnings Diluted Growth Ratio | 0.011 | 0.094 | 0.039 | 0.373 | 0.129 | |
| Price To Book Ratio | -1.146 | -1.355 | -3.829 | 29.615 | 71.914 | |
| Price To Sales Ratio | 26.093 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.712 | -1.440 | -1.287 | -4.565 | -6.107 | |
| Price To Operating Cash Flow Ratio | -0.712 | -1.440 | -1.287 | -4.565 | -6.107 | |
| Debt To Assets Ratio | 1.625 | 1.032 | 1.101 | 0.384 | 0.522 | |
| Debt To Equity Ratio | -0.938 | -0.407 | -2.463 | 1.254 | 2.584 | |
| Debt To Capital Ratio | -15.151 | -0.686 | 1.684 | 0.556 | 0.721 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.703 | |
| Financial Leverage Ratio | -0.577 | -0.394 | -2.237 | 3.265 | 4.951 | |
| Working Capital Turnover Ratio | -0.065 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.131 | -1.617 | -0.920 | -2.873 | -8.035 | |
| Operating Cash Flow Sales Ratio | -36.667 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -2.052 | -2.212 | -1.546 | -5.189 | -27.991 | |
| Interest Coverage Ratio | -236.860 | -22.712 | -34.055 | -42.415 | -55.256 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.731 | -2.337 | -1.209 | -5.192 | -60.001 | |
| Operating Cash Flow Coverage Ratio | -1.717 | -2.313 | -1.209 | -5.172 | -4.558 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.928 | -1.579 | -1.176 | -3.920 | -6.382 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 46.5% | ▲46.5% | ▲37.2% |
| Ebit Margin | -4506.0% | ▼-4506.0% | ▼-3604.8% |
| Ebitda Margin | -4497.7% | ▼-4497.7% | ▼-3598.2% |
| Operating Profit Margin | -4744.2% | ▼-4744.2% | ▼-3795.4% |
| Pretax Profit Margin | -4526.0% | ▼-4526.0% | ▼-3620.8% |
| Continuous Operations Profit Margin | -4416.2% | ▼-4416.2% | ▼-3533.0% |
| Net Profit Margin | -4416.2% | ▼-4416.2% | ▼-3533.0% |
| Bottom Line Profit Margin | -4416.2% | ▼-4416.2% | ▼-3533.0% |
| Current Ratio | 0.380 | ▼-0.265 | ▼-0.874 |
| Quick Ratio | 0.307 | ▼-0.338 | ▼-0.932 |
| Solvency Ratio | -1.227 | ▼-0.489 | ▲0.665 |
| Cash Ratio | 0.176 | ▼-0.174 | ▼-0.634 |
| Price To Earnings Ratio | -0.592 | ▲0.723 | ▲2.007 |
| Price To Earnings Growth Ratio | 0.011 | ▼-0.084 | ▼-0.119 |
| Forward Price To Earnings Growth Ratio | 0.011 | ▼-0.084 | ▼-0.119 |
| Price To Earnings Diluted Ratio | -0.592 | ▲0.723 | ▲2.007 |
| Price To Earnings Diluted Growth Ratio | 0.011 | ▼-0.084 | ▼-0.119 |
| Price To Book Ratio | -1.146 | ▲0.210 | ▼-20.186 |
| Price To Sales Ratio | 26.093 | ▲26.093 | ▲20.875 |
| Price To Free Cash Flow Ratio | -0.712 | ▲0.728 | ▲2.110 |
| Price To Operating Cash Flow Ratio | -0.712 | ▲0.728 | ▲2.110 |
| Debt To Assets Ratio | 1.625 | ▲0.593 | ▲0.692 |
| Debt To Equity Ratio | -0.938 | ▼-0.531 | ▼-0.944 |
| Debt To Capital Ratio | -15.151 | ▼-14.464 | ▼-12.575 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.141 |
| Financial Leverage Ratio | -0.577 | ▼-0.183 | ▼-1.579 |
| Working Capital Turnover Ratio | -0.065 | ▼-0.065 | ▼-0.052 |
| Operating Cash Flow Ratio | -1.131 | ▲0.485 | ▲1.784 |
| Operating Cash Flow Sales Ratio | -36.666 | ▼-36.666 | ▼-29.333 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | -2.052 | ▲0.160 | ▲5.746 |
| Interest Coverage Ratio | -236.860 | ▼-214.148 | ▼-158.600 |
| Short Term Operating Cash Flow Coverage Ratio | -1.731 | ▲0.606 | ▲12.363 |
| Operating Cash Flow Coverage Ratio | -1.716 | ▲0.597 | ▲1.277 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.928 | ▲0.651 | ▲1.869 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $36.9M | $99.1M | $55.3M | $258.7M | $331.3M | |
| Enterprise value | $59.0M | $113.9M | $67.4M | $252.3M | $328.7M | |
| EV / Sales | 41.74x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -1.14x | -1.66x | -1.57x | -4.45x | -6.06x | |
| EV / Free cash flow | -1.14x | -1.66x | -1.57x | -4.45x | -6.06x | |
| EV / EBITDA | -0.93x | -1.58x | -1.18x | -3.92x | -6.38x | |
| Net debt / EBITDA | -0.35x | -0.20x | -0.21x | 0.10x | 0.05x | |
| Current ratio | 0.38x | 0.64x | 0.66x | 1.40x | 3.19x | |
| Income quality | 0.83x | 0.91x | 0.73x | 0.86x | 1.02x | |
| Graham net-net | -$1 | -$5 | -$2 | -$0 | -$0 | |
| Tax burden | 97.6% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.4% | 104.4% | 102.7% | 102.3% | 102.8% | |
| Working capital | -$28.4M | -$15.1M | -$15.8M | $7.8M | $14.8M | |
| Invested capital | -$28.2M | -$14.9M | -$15.7M | $7.9M | $15.0M | |
| Return on assets | -335.9% | -261.5% | -182.6% | -231.5% | -233.1% | |
| Operating ROA | -282.9% | -234.6% | -174.7% | -245.7% | -243.2% | |
| Return on tangible assets | -335.9% | -261.5% | -182.6% | -231.5% | -233.1% | |
| Return on equity | 193.9% | 103.1% | 408.5% | -756.0% | -1154.0% | |
| Return on invested capital | -2357.6% | -455.0% | -251.5% | -319.3% | -303.7% | |
| Return on capital employed | 246.3% | 522.2% | 368.1% | -716.9% | -322.1% | |
| Earnings yield | -169.2% | -76.1% | -106.7% | -25.5% | -16.0% | |
| Free cash flow yield | -140.5% | -69.5% | -77.7% | -21.9% | -16.4% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 2825.4% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 1922884116.8% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 629.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 385d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 4919d | 25545d | 54307d | 6226d | 3058d | |
| Operating cycle | 1996d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -2923d | -25545d | -54307d | -6226d | -3058d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-62.8%EV / Sales n/aEV / EBITDA ▲+41.2%EV / Op. cash flow ▲+0.517Earnings yield ▼-0.932
Profitability
Return on equity ▲+0.908Return on assets ▼-0.744Return on invested capital ▼-19.027Return on capital employed ▼-2.759Operating ROA ▼-0.483Income quality ▼-0.083Tax burden ▼-0.024
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-20626.715Operating cycle n/aCash conversion cycle ▲+22622.792Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.265Net debt / EBITDA ▼-0.142Working capital ▼-13287943.000Invested capital ▼-13337080.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-88.9%EV / Sales n/aEV / EBITDA ▲+85.5%EV / Op. cash flow ▲+4.921Earnings yield ▼-1.532
Profitability
Return on equity ▲+13.479Return on assets ▼-1.028Return on invested capital ▼-20.539Return on capital employed ▲+5.684Operating ROA ▼-0.397Income quality ▼-0.190Tax burden ▼-0.024
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+1860.604Operating cycle n/aCash conversion cycle ▲+135.473Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.806Net debt / EBITDA ▼-0.398Working capital ▼-43181783.000Invested capital ▼-43231329.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-08-17 OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
- 2026-08-16 Oncobiologics Q3 Earnings Call Highlights Oncobiologics (NASDAQ: OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States. President and Chief Executive Officer Bob Jahr called the approval
- 2026-08-15 Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN) enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 64.2% of enGene shares are
- 2026-08-14 Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
- 2026-08-14 Oncobiologics Q3 Earnings Call Highlights Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States.
- 2026-08-14 Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.44 per share a year ago.
- 2026-08-14 Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
- 2026-08-14 Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street''s Most Accurate Analysts Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
- 2026-08-12 Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined public offering price of each share of common stock and accompanying warrant to purchase one share is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisable immediately and will expire five years from the date of issuance. Outlook Therapeutics also granted the underwriters an option for a period of 30 days to purchase up to 8,333,333 additional shares of its common stock and/or warrants to purchase up to 8,333,333 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are to be sold by Outlook Therapeutics. The offering is expected to close on August 14, 2026 subject to market and other conditions.
- 2026-08-12 Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to fifteen percent (15%) of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering are to be sold by Outlook Therapeutics. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.